- Home
- MLYS vs KNSA Comparison
MLYS vs KNSA Comparison
Compare MLYS & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- KNSA
- Stock Information
- Founded
- MLYS 2019
- KNSA 2015
- Country
- MLYS United States
- KNSA United Kingdom
- Employees
- MLYS N/A
- KNSA N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- KNSA Health Care
- Exchange
- MLYS Nasdaq
- KNSA Nasdaq
- Market Cap
- MLYS 2.9B
- KNSA 2.6B
- IPO Year
- MLYS 2023
- KNSA 2018
- Fundamental
- Price
- MLYS $40.40
- KNSA $40.38
- Analyst Decision
- MLYS Strong Buy
- KNSA Strong Buy
- Analyst Count
- MLYS 6
- KNSA 7
- Target Price
- MLYS $46.40
- KNSA $49.71
- AVG Volume (30 Days)
- MLYS 1.5M
- KNSA 523.8K
- Earning Date
- MLYS 11-10-2025
- KNSA 10-28-2025
- Dividend Yield
- MLYS N/A
- KNSA N/A
- EPS Growth
- MLYS N/A
- KNSA N/A
- EPS
- MLYS N/A
- KNSA 0.47
- Revenue
- MLYS N/A
- KNSA $597,973,000.00
- Revenue This Year
- MLYS N/A
- KNSA $62.63
- Revenue Next Year
- MLYS N/A
- KNSA $29.93
- P/E Ratio
- MLYS N/A
- KNSA $86.37
- Revenue Growth
- MLYS N/A
- KNSA 55.68
- 52 Week Low
- MLYS $8.24
- KNSA $17.82
- 52 Week High
- MLYS $47.65
- KNSA $42.05
- Technical
- Relative Strength Index (RSI)
- MLYS 49.69
- KNSA 61.41
- Support Level
- MLYS $36.56
- KNSA $37.61
- Resistance Level
- MLYS $47.65
- KNSA $41.27
- Average True Range (ATR)
- MLYS 3.45
- KNSA 1.66
- MACD
- MLYS -0.00
- KNSA 0.14
- Stochastic Oscillator
- MLYS 50.18
- KNSA 84.78
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.